• Leveljump Healthcare (JUMP) has agreed to acquire an additional 7.82 per cent minority equity interest in Real Time Medical (RTM) increasing its ownership stake to 24.71 per cent
  • Leveljump will issue 1,335,961 units to RTM
  • Leveljump has also agreed to purchase a $100,000 promissory note
  • LevelJump Healthcare Corp. (JUMP) opened trading at C$0.11 per share
  • Leveljump is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology

Leveljump Healthcare (JUMP) has agreed to acquire an additional 7.82 per cent minority equity interest in Real Time Medical.

Leveljump will issue 1,335,961 units to Real Time Medical. Each unit, issued at a price of $0.65, will consist of five Leveljump common shares and one share purchase warrant. Each warrant will entitle the holder to acquire one additional common share of Leveljump at a price of $0.35 on or before December 31, 2023.

Upon the closing of the purchase, Leveljump will own a 24.71 per cent interest in Real Time Medical.

Closing of the RTM purchase is subject to the consent of the TSXV and the board of directors of RTM.

In addition to the purchase of the RTM shares, Leveljump has agreed to purchase a $100,000 promissory note with accrued interest of approximately $30,000. Leveljump will pay $50,000 to the note holder upon closing of the purchase of the RTM shares and the balance of the note principal and accrued interest on or before June 30, 2022.

Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology.

LevelJump Healthcare Corp. (JUMP) opened trading at C$0.11 per share.

More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.